Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009931 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01009931 is a Phase 2 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 1 participants.
The verdict
NCT01009931, a Phase 2 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute myeloid leukemia.
Interventions
- DRUG Dexamethasone
- DRUG 12-O-tetradecanoylphorbol-13-acetate
- DRUG Choline magnesium trisalicylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01009931
The ClinicalTrials.gov registry entry for NCT01009931 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01009931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01009931 about?
NCT01009931 is a clinical study titled "Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies". This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute myeloid leukemia.
What is the current status of trial NCT01009931?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2011-03. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01009931?
The interventions under investigation include: Dexamethasone (DRUG), 12-O-tetradecanoylphorbol-13-acetate (DRUG), Choline magnesium trisalicylate (DRUG).
Who is sponsoring clinical trial NCT01009931?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.